Literature DB >> 23430892

Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates.

Valentina Paracchini1, Manuela Seia, Sara Raimondi, Lucy Costantino, Patrizia Capasso, Luigi Porcaro, Carla Colombo, Domenico A Coviello, Tiziana Mariani, Emanuela Manzoni, Monica Sangiovanni, Carlo Corbetta.   

Abstract

The IRT screening test for the use in diagnosing newborns with CF has a high sensitivity but is not very specific resulting in a large number of screened positive infants found to have a normal sweat test. The aim of this study was to analyze the differences in b-IRT levels among different groups of newborns positive to NBS.Population data included all b-IRT positive (>99th centile) neonates born in Lombardia from 2000 to 2007. The hypertrypsinemic newborns were divided into four groups, according to CF status (noncarrier, carrier, CFTR-RD, CF).Among a total of 717,172 newborns screened within the study period, 7,354 newborns were found positive to NBS and were included in the study. An overall statistically significant difference in b-IRT levels was found among the four groups (p < 0.001), while b-IRT values did not differ between noncarriers and carriers. b-IRT levels had a low predictive accuracy in correctly identifying the four different groups (c-index: 0.60), but the accuracy was high in discriminating between classic CF and carrier or noncarrier status in neonates positive to NBS. The IRT level on the initial blood specimen obtained at birth differs based on the CF genotype, although a wide range of individual variation may occur.

Entities:  

Year:  2011        PMID: 23430892      PMCID: PMC3509858          DOI: 10.1007/8904_2011_55

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  20 in total

1.  Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.

Authors:  I Lecoq; J Brouard; D Laroche; C Férec; G Travert
Journal:  Acta Paediatr       Date:  1999-03       Impact factor: 2.299

2.  Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.

Authors:  Carlo Castellani; Luigi Picci; Maurizio Scarpa; Maria Cristina Dechecchi; Luisa Zanolla; Baroukh Maurice Assael; Franco Zacchello
Journal:  Am J Med Genet A       Date:  2005-06-01       Impact factor: 2.802

3.  Homozygosity for L997F in a child with normal clinical and chloride secretory phenotype provides evidence that this cystic fibrosis transmembrane conductance regulator mutation does not cause cystic fibrosis.

Authors:  N Derichs; A Schuster; I Grund; A Ernsting; C Stolpe; S Körtge-Jung; S Gallati; M Stuhrmann; P Kozlowski; M Ballmann
Journal:  Clin Genet       Date:  2005-06       Impact factor: 4.438

4.  Sweat testing infants detected by cystic fibrosis newborn screening.

Authors:  Richard B Parad; Anne Marie Comeau; Henry L Dorkin; Mark Dovey; Robert Gerstle; Thomas Martin; Brian P O'Sullivan
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

5.  Molecular and clinical features associated with CFTR gene rearrangements in Italian population: identification of a new duplication and recurrent deletions.

Authors:  V Paracchini; M Seia; D Coviello; L Porcaro; L Costantino; P Capasso; D Degiorgio; R Padoan; C Corbetta; L Claut; D Costantini; C Colombo
Journal:  Clin Genet       Date:  2008-02-13       Impact factor: 4.438

6.  A survey of newborn screening for cystic fibrosis in Europe.

Authors:  Kevin W Southern; Anne Munck; Rodney Pollitt; Georges Travert; Luisa Zanolla; Jeannette Dankert-Roelse; Carlo Castellani
Journal:  J Cyst Fibros       Date:  2006-07-25       Impact factor: 5.482

7.  Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results.

Authors:  Ruslan Dorfman; Weili Li; Lei Sun; Fan Lin; Yongqian Wang; Andrew Sandford; Peter D Paré; Karen McKay; Hana Kayserova; Tereza Piskackova; Milan Macek; Kamila Czerska; Dorota Sands; Harm Tiddens; Sonia Margarit; Gabriela Repetto; Marci K Sontag; Frank J Accurso; Scott Blackman; Garry R Cutting; Lap-Chee Tsui; Mary Corey; Peter Durie; Julian Zielenski; Lisa J Strug
Journal:  Hum Genet       Date:  2009-12       Impact factor: 4.132

8.  Cystic fibrosis mutations with widely variable phenotype: the D1152H example.

Authors:  H Mussaffi; D Prais; M Mei-Zahav; H Blau
Journal:  Pediatr Pulmonol       Date:  2006-03

9.  Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.

Authors:  Rita Padoan; Alessandra Bassotti; Manuela Seia; Carlo Corbetta
Journal:  Eur J Pediatr       Date:  2002-04       Impact factor: 3.183

10.  Neonatal screening for cystic fibrosis: addition of molecular diagnostics to increase specificity.

Authors:  W C Spence; J Paulus-Thomas; D M Orenstein; E W Naylor
Journal:  Biochem Med Metab Biol       Date:  1993-04
View more
  5 in total

Review 1.  Newborn screening and diagnosis of mucopolysaccharidoses.

Authors:  Shunji Tomatsu; Tadashi Fujii; Masaru Fukushi; Toshihiro Oguma; Tsutomu Shimada; Miho Maeda; Kazuhiro Kida; Yuniko Shibata; Hideyuki Futatsumori; Adriana M Montaño; Robert W Mason; Seiji Yamaguchi; Yasuyuki Suzuki; Tadao Orii
Journal:  Mol Genet Metab       Date:  2013-06-21       Impact factor: 4.797

2.  Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.

Authors:  Issa Siryani; Mohamed Jama; Nisreen Rumman; Hiyam Marzouqa; Moein Kannan; Elaine Lyon; Musa Hindiyeh
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

3.  Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience.

Authors:  Chiara Bianchimani; Daniela Dolce; Claudia Centrone; Silvia Campana; Novella Ravenni; Tommaso Orioli; Erica Camera; Gianfranco Mergni; Cristina Fevola; Paolo Bonomi; Giovanni Taccetti; Vito Terlizzi
Journal:  Int J Neonatal Screen       Date:  2022-08-03

4.  Screening for cystic fibrosis in New York State: considerations for algorithm improvements.

Authors:  Denise M Kay; Breanne Maloney; Rhonda Hamel; Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Emily McGrath; Lea Krein; Beth Vogel; Carlos A Saavedra-Matiz; Michele Caggana; Norma P Tavakoli
Journal:  Eur J Pediatr       Date:  2015-08-21       Impact factor: 3.183

5.  Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial.

Authors:  Jane C Davies; Claire E Wainwright; Gregory S Sawicki; Mark N Higgins; Daniel Campbell; Christopher Harris; Paul Panorchan; Eric Haseltine; Simon Tian; Margaret Rosenfeld
Journal:  Am J Respir Crit Care Med       Date:  2021-03-01       Impact factor: 21.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.